Toceranib Phosphate 874819-74-6 — China API Manufacturer | Veterinary API R&D to Production

China Manufacturing Landscape for Toceranib Phosphate

Toceranib Phosphate (CAS 874819-74-6), marketed as Palladia, is a multi-targeted receptor tyrosine kinase inhibitor approved for the treatment of canine mast cell tumors and increasingly investigated for broader veterinary oncology applications. As companion animal healthcare spending grows globally and cancer treatment protocols for pets become more sophisticated, demand for Toceranib Phosphate API has expanded significantly. Chinese pharmaceutical manufacturers have responded by developing quality-controlled synthesis capabilities for this complex small molecule, providing veterinary pharmaceutical companies worldwide with a cost-effective and reliable API source.

Our facility specializes in the synthesis of advanced veterinary oncology APIs, with Toceranib Phosphate representing one of our flagship products in this therapeutic category. China’s mature organic chemistry synthesis infrastructure, combined with expertise in multi-step heterocyclic chemistry and chiral separation technologies, enables production of this structurally complex API at quality levels and price points that support the growth of accessible veterinary cancer treatment globally.

Manufacturing Process & Facility

Toceranib Phosphate synthesis involves a multi-step organic chemistry route encompassing construction of the indolinone core structure, introduction of the pyrrole-substituted side chain via palladium-catalyzed cross-coupling reactions, and subsequent functional group elaboration to build the complete molecular architecture. Key synthetic challenges include regioselective substitution on the indolinone ring, control of Z/E geometry at the critical vinylic position, and phosphate salt formation under conditions that yield the desired crystalline polymorph.

The manufacturing facility is equipped with glass-lined and stainless steel reactors (100 L to 2,000 L), Pd catalyst recovery systems for sustainable and cost-effective cross-coupling chemistry, preparative chromatography systems, and controlled-atmosphere crystallization equipment. All production is conducted under NMPA pharmaceutical conditions in dedicated suites with ISO Class 7 cleanroom classification for final processing steps. Current annual production capacity is 200 kg of Toceranib Phosphate API, scalable based on demand.

Quality Standards & Multi-Pharmacopeial Compliance

Toceranib Phosphate is manufactured to meet veterinary pharmaceutical quality standards equivalent to the specifications published by the original innovator and aligned with general pharmacopeial requirements for veterinary APIs. HPLC purity consistently exceeds 99.0%, with the geometric isomer (E-isomer) and process-related impurities controlled below 0.15% individually. Palladium residues from cross-coupling reactions are controlled below 10 ppm through validated scavenger and purification protocols, meeting ICH Q3D elemental impurity guidelines.

Quality testing encompasses HPLC assay and related substances profiling, chiral and geometric isomer analysis, residual Pd and other elemental impurities by ICP-MS, residual solvents by headspace GC, phosphate content verification, water content by Karl Fischer, polymorphic form identification by XRPD, and microbial limits testing. Stability studies under ICH-aligned conditions support a 24-month retest period at controlled room temperature storage.

Regulatory Documentation

Regulatory documentation packages for Toceranib Phosphate are structured to support veterinary pharmaceutical registrations in all major markets. Documentation includes Veterinary Drug Master Files, detailed manufacturing process descriptions in CTD-V format, analytical method validation reports, forced degradation study data, and complete stability data packages. quality certificates, impurity characterization and qualification data, and material of origin declarations are provided as standard. Technical support for customer regulatory submissions, including responses to deficiency queries from regulatory authorities, is provided as part of our customer service commitment.

Packaging & Logistics

Toceranib Phosphate API is packaged in pharmaceutical-grade HDPE bottles or double PE bags within aluminum-lined fiber drums, in quantities of 100 g, 500 g, 1 kg, and 5 kg per unit. Light-protective secondary packaging is employed to prevent photodegradation. Shipments are dispatched via air freight from Shanghai or Guangzhou airports, with typical international delivery timelines of 5-10 business days. Full export documentation including MSDS, CoA, veterinary health certificates, and customs clearance support documentation is provided with every shipment.

Competitive Pricing & Supply Reliability

As a direct manufacturer without trading intermediaries, we offer Toceranib Phosphate at pricing that reflects actual production costs plus reasonable manufacturer margins. Development-stage pricing for initial evaluation quantities (10-100 g) is available to support formulation development programs, with commercial-scale pricing for ongoing supply commitments. Lead times are typically 4-6 weeks for standard orders. The veterinary oncology API market segment is a strategic focus for our facility, and production capacity investments are planned to ensure supply capability grows in alignment with market demand. Multi-year supply agreements with guaranteed capacity allocation are available for strategic customers.

Toceranib Phosphate Specifications